

## Management Response

<b>Evaluation Title</b>	The Medicines Transparency Alliance - Programmatic Review of MeTA Phase II
<b>Commissioning Unit</b>	EMP/PAU
<b>Link to the evaluation</b>	<a href="http://apps.who.int/iris/handle/10665/246256">http://apps.who.int/iris/handle/10665/246256</a>
<b>Unit Responsible for providing the management response</b>	EMP/PAU
<b>Overall Management Response:</b> WHO has supported the MeTA project in the 7 participating countries since its inception in 2009, firstly through the provision of technical support and later through both the provision of technical support and through participation in the management of the programme. A programme evaluation was carried out to gain insight from external reviewers on the achievements and challenges of MeTA Phase II and to inform WHO strategy for future work in transparency and multi-stakeholder engagement in the pharmaceutical sector in countries. Principal conclusions of the programme evaluation include: <ul style="list-style-type: none"> <li>- Phase II achieved its aims in transparency and multi-stakeholder policy dialogue</li> <li>- Improved transparency through a multi-stakeholder approach is an example of good governance best practice</li> <li>- Processes could be improved for more impact and better value for money</li> </ul> A total of 28 detailed recommendations were made with the overall recommendations as follows: <ul style="list-style-type: none"> <li>- WHO should use the experiences and lessons learnt from MeTA to promote the roles of multi-sectoral councils as key drivers of change in national medicines policies, particularly their roles in promoting transparency, accountability and policy dialogue.</li> <li>- WHO should consider integrating a MeTA approach into its wider work on transparency and good governance in medicines.</li> </ul> Management agrees with the recommendations.	
<b>Management Response Status</b>	In progress
<b>Date</b>	27 February 2017

## Recommendations and Action Plan

<b>Recommendation 1</b>				
WHO should use the experiences and lessons learnt from MeTA to promote the roles of multi-sectoral councils as key drivers of change in national medicines policies, particularly their roles in promoting transparency, accountability and policy dialogue.				
<b>Management response</b>	- Accepted - Further work was planned to explore the lessons learnt and to share and promote the lessons learnt			
<b>Status</b>	In progress			
<b>Key actions</b>	Responsible	Timeline	Status	Comments
A review was developed and published: Medicines Transparency Alliance (MeTA): Pathways to Transparency, Accountability and Access Cross-Case Analysis and Review of Phase II	EMP/OOD/PGK	Completed	Implemented	
Peer reviewed journal articles, abstracts and advocacy planned	EMP/OOD/PGK	2017	In progress	

<b>Recommendation 2</b>				
WHO should consider integrating a MeTA approach into its wider work on transparency and good governance in medicines				
<b>Management response</b>	- Accepted - Further work was planned to improve support for the collection of robust information, transparency and multi-stakeholder approaches			
<b>Status</b>	In progress			
<b>Key actions</b>	Responsible	Timeline	Status	Comments
Development of mobile phone application for the collection of medicines price and availability data	EMP/IAU	Ongoing	In progress	- At least 15 countries have used the application to collect data. Scale up is funding dependent
Transparency in pricing of pharmaceuticals will be explored through the Fair Pricing Forum	EMP/IAU	May 2017	In progress	
Multi-stakeholder approaches incorporated into the Good Governance for Medicines programme	EMP/OOD/PGK	Ongoing	In progress	